Moderna co-founder, ex-Bayer CEO jump aboard Belgian RNA biotech, investing in Series B round
As mRNA has taken a more prominent perch thanks to the Covid-19 pandemic, a European biotech has now landed two people to its board of directors to bring its efforts up to speed.
ETheRNA announced Tuesday that it raised $39 million in a Series B2 round, securing two big-name investors: Moderna co-founder Kenneth Chien and ex-Bayer and Thermo Fisher CEO Marijn Dekkers. Both of them are joining the biotech’s board of directors, according to a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.